Insider · CIK 0001864159
Andrew Hollman Meyer
officer
Files at JANX (Janux Therapeutics, Inc.). First filing Jan 3, 2025, latest Mar 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $980k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JANX: Janux Therapeutics, Inc.
JANXOct 9, 2026 · close 18.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Janux Therapeutics, Inc. | $107k 3,334 shares | -4% | - | |
| 0Weak | Janux Therapeutics, Inc. | $141k 3,334 shares | -4% | - | |
| 29Weak | Janux Therapeutics, Inc. | $732k 13,334 shares | -14% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,334 | $4.21 | $14k | 85,473 | Mar 5, 2025 |
| Mar 3, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,433 | $31.88 | $78k | 83,040 | Mar 5, 2025 |
| Mar 3, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -901 | $32.85 | $30k | 82,139 | Mar 5, 2025 |
| Mar 3, 2025 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,334 | $0.00 | $0 | 93,999 | Mar 5, 2025 |
| Feb 3, 2025 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,334 | $4.21 | $14k | 85,473 | Feb 5, 2025 |
| Feb 3, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,418 | $42.08 | $102k | 83,055 | Feb 5, 2025 |
| Feb 3, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -816 | $42.77 | $35k | 82,239 | Feb 5, 2025 |
| Feb 3, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -100 | $43.60 | $4,360 | 82,139 | Feb 5, 2025 |
| Feb 3, 2025 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,334 | $0.00 | $0 | 97,333 | Feb 5, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +18,000 | $0.00 | $0 | 95,473 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,922 | $53.76 | $157k | 92,551 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,768 | $54.51 | $314k | 86,783 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,444 | $55.76 | $192k | 83,339 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $56.78 | $57k | 82,339 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -200 | $57.37 | $11k | 82,139 | Jan 3, 2025 |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +63,000 | $0.00 | $0 | 63,000 | Jan 3, 2025 |
| Dec 19, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +9,880 | $20.24 | $200k | 77,472 | Dec 20, 2024 |
| Dec 19, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +1 | $14.02 | $14 | 77,473 | Dec 20, 2024 |
| Dec 19, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -9,880 | $0.00 | $0 | 96,870 | Dec 20, 2024 |
| Dec 19, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -1 | $0.00 | $0 | 89,999 | Dec 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.